Status
Conditions
Treatments
About
Next generation real-time monitoring for PrEP adherence in young Kenyan women
Full description
This protocol describes a longitudinal study of young Kenyan women at high risk for HIV who will be offered HIV pre-exposure prophylaxis (PrEP) for up to two years. Adherence will be monitored in all women with the next generation Wisepill; half will be randomized to receive short message service (SMS) reminders. The technical function, acceptability, cost, and validity of the next generation Wisepill device coupled to SMS reminders will be determined among this cohort of young Kenyan women. Additionally, SMS will be used for longitudinal assessment of risk perception and its alignment with PrEP adherence.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
HIV-uninfected (as determined by Kenya national testing algorithms)
Wanting to start PrEP with an initial recommendation of 6 months of use
Clinically safe to receive PrEP, in accordance with Centers for Disease Control and Prevention (CDC) guidelines:
Sexually active (defined as vaginal or anal sex) within the last 3 months
At high risk for HIV infection based on a validated risk score of >5 or being in an HIV serodiscordant relationship
Not pregnant
Owns a personal cell phone (not shared) compatible with study protocols and the ability to charge it
Ability to send a text message
Intending to stay in the area for at least the next year
Willing to use study criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
348 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal